Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Rubella and Congenital Rubella Syndrome

Generalities
Agent Rubella virus, genus Rubullovirus, family Togaviridae
Incubation period 14-17 days (range 14-21 days)
Period of transmissibility - 7 days before rash and 4 days after rash onset
- From congenital rubella: infants shed the virus for several months after birth
Reservoir Humans
Modes of transmission - Person-to-person: direct contact with droplets
- Infants with Congenital Rubella Syndrome shed large quantities of virus in their pharyngeal secretions and urine.
- Materno-foetal transmission: 90% of infants born to women infected with rubella during the 1st trimester. The risk of transmission is 10-20% by the 16th week, and rare after the 20th week.
Clinical presentation - Febril maculo-papular rash
- Complications: thrombocytopenia (1/3000), post-infectious encephalitis (1/6000), rarely chronic arthritis
- Congenital Rubella Syndrome: Congenital malformation as deafness, cataracts, microphtalmia, congenital glaucoma, pigmentary retinopathy, nystagmus, microcephaly, meningo-encephalitis, mental retardation, patent ductus arteious, atrial or ventricular septal defects, other congenital heart disease, purpura, hepatosplenomegaly, jaundice, radiolucent bone disease
Resources
Case definitions - MOPH circular no 12 (2013): Acquired Rubella
- MOPH circular no 45 (2007): Congenital Rubella Syndrome
Forms - Rash reporting form
- CRS reporting form
- Rash investigation form
- CRS investigation form
Data - Rubella 2021
- Rubella 2020
- Rubella 2019
- Rubella 2018
- Rubella 2017
- Rubella 2016
- Rubella 2015
 
    ...
    58
    ...
ATC Name B/G Ingredients Dosage Form Price
J06BB04 IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB BioHuman Hepatitis B immunoglobulin (human) - 100UI/ml 100UI/ml Injectable solution 6,853,730 L.L
N02AA05 OXYNORM B Oxycodone HCl - 10mg/ml 10mg/ml Injectable solution 1,584,390 L.L
B05CX01 DEXTROSE 10% INJECTION, USP G Glucose - 10% 10% Injectable solution 191,913 L.L
J01GB06 MIACIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable solution 2,015,764 L.L
J06BB04 IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB BioHuman Hepatitis B immunoglobulin (human) - 500UI/5ml 500UI/5ml Injectable solution 26,599,935 L.L
N02AA05 OXYCODONE RENAUDIN G Oxycodone HCl - 10mg/10ml 10mg/10ml Injectable solution 2,432,355 L.L
B05CX01 DEXTROSE 10% INJECTION, USP G Glucose - 10% 10% Injectable solution 168,929 L.L
J01GB06 ORLOBIN G Amikacin (sulfate) - 500mg/2ml 500mg/2ml Injectable solution 329,241 L.L
B05CX01 DEXTROSE G Dextrose, H2O - 20g/100ml 20g/100ml Injectable solution 369,209 L.L
J06BD01 SYNAGIS BioTech Palivizumab - 100mg/ml 100mg/ml Injectable solution 57,429,464 L.L
N02AB02 PETHIDIN PANPHARMA G Pethidine HCl - 50mg/ml 50mg/ml Injectable solution 862,747 L.L
A10BJ02 SAXENDA BioTech Liraglutide - 6mg/ml 6mg/ml Injectable solution 16,747,035 L.L
B05CX01 DEXTROSE 20% INJECTION USP G Glucose - 20% 20% Injectable solution 316,025 L.L
J06BD01 SYNAGIS BioTech Palivizumab - 50mg/0.5ml 50mg/0.5ml Injectable solution 38,316,693 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 0.75mg/0.5ml 0.75mg/0.5ml Injectable solution 10,165,201 L.L
B01AX05 ARIXTRA B Fondaparinux sodium - 2.5mg/0.5ml 2.5mg/0.5ml Injectable solution 5,341,774 L.L
B05CX01 DEXTROSE 20% INJECTION USP G Glucose - 20% 20% Injectable solution 183,869 L.L
L03AA02 NEOGRASTIM 30 BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 1,970,969 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 1.5mg/0.5ml 1.5mg/0.5ml Injectable solution 10,165,201 L.L
B01AX05 ARIXTRA B Fondaparinux sodium - 7.5mg/0.6ml 7.5mg/0.6ml Injectable solution 12,004,668 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
J07AH08 MENACTRA MENINGOCOCCAL POLYSACCHARIDE DIPHTERIA TOXOID CONJUGATE VACCINE B Meningococcal Polysaccharides (serogroups A, C, Y and W-135) - 4mcg/0.5ml each, Diphteria Toxoid Protein - 48mcg/0.5ml Injectable solution 6,144,048 L.L
L03AA02 NEUTROMAX BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 2,553,301 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 3mg/0.5ml 3mg/0.5ml Injectable solution 10,165,201 L.L
B02AA02 EXACYL B Tranexamic acid - 500mg/5ml 500mg/5ml Injectable solution 748,520 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 148,244 L.L
L03AA02 NEUPOGEN BioTech Filgrastim - 300mcg/0.5ml 300mcg/0.5ml Injectable solution 5,250,393 L.L
A10BJ05 TRULICITY BioTech Dulaglutide - 4.5mg 4.5mg/0.5ml Injectable solution 10,165,201 L.L
B05CX01 5% DEXTROSE INJECTION USP G Glucose - 5% 5% Injectable solution 159,736 L.L
J07AH08 MENQUADFI G Meningococcal (serogroups A, C, W and Y) conjugate vaccine - Injectable solution 4,859,334 L.L
    ...
    58
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025